Jia Ru, Zhao Chuan-Hua, Li Pan-Song, Liu Rong-Rui, Zhang Yun, Chen Hai-E, Chang Lian-Peng, Gong Yu-Hua, Guan Yan-Fang, Yi Xin, Xu Jian-Ming
Department of Gastrointestinal Oncology, The Fifth Medical Centre, Chinese People's Liberation Army General Hospital, Fengtai, Beijing 100071, P.R. China.
Geneplus-Beijing Institute, Changping, Beijing 102206, P.R. China.
Oncol Lett. 2021 Jan;21(1):68. doi: 10.3892/ol.2020.12329. Epub 2020 Nov 25.
Esophageal squamous cell carcinoma (ESCC) is a highly malignant and deadly tumor. Radiation therapy is one of the primary treatments for locally advanced ESCC. However, the biomarkers for prognosis of definitive radiation remain undefined. Peripheral blood circulating tumor (ct)DNA provides information of tumor genetic alterations and has been confirmed as a potential non-invasive biomarker for several types of cancer. The present study investigated the clinical implications of ctDNA detection in patients with ESCC and receiving definitive radiation therapy. Patients with locally advanced ESCC were retrospectively recruited. Plasma samples were collected before, during and following radiation therapy. Next-generation sequencing was performed to identify somatic mutations in 180 genes. A total of 69 baseline and post-radiation plasma samples were collected from 25 patients. A total of 59 non-silent single nucleotide variants were present in 33 genes. All pre-radiation and 58.3% (14/24) of post-radiation samples had at least one mutation. Patients with lymph node metastases (LNM) exhibited a higher number of pre-radiation mutations compared with those without LNM. The variables, progression-free survival (PFS) and overall survival (OS) of the patients with one baseline mutation were not significantly different compared with that in patients with more than one baseline mutation. Patients with initial ctDNA-positive post-radiation samples exhibited significantly reduced PFS (P=0.047) and OS (P=0.005) compared with that in patients with ctDNA-negative samples. The post-radiation plasma ctDNA status was an independent prognostic factor from univariate and multivariate analyses. Dynamic monitoring of ctDNA during follow-up was examined. The results indicated that ctDNA was a predictive and prognostic marker in patients with ESCC and receiving definitive radiation therapy, which may guide subsequent treatment.
食管鳞状细胞癌(ESCC)是一种高度恶性且致命的肿瘤。放射治疗是局部晚期ESCC的主要治疗方法之一。然而,根治性放疗预后的生物标志物仍不明确。外周血循环肿瘤(ct)DNA提供肿瘤基因改变的信息,并已被确认为几种癌症的潜在非侵入性生物标志物。本研究调查了ctDNA检测在接受根治性放疗的ESCC患者中的临床意义。回顾性招募局部晚期ESCC患者。在放疗前、放疗期间和放疗后收集血浆样本。进行二代测序以鉴定180个基因中的体细胞突变。共从25例患者中收集了69份基线和放疗后血浆样本。33个基因中共有59个非沉默单核苷酸变异。所有放疗前样本和58.3%(14/24)的放疗后样本至少有一个突变。有淋巴结转移(LNM)的患者与无LNM的患者相比,放疗前的突变数量更多。有一个基线突变的患者的无进展生存期(PFS)和总生存期(OS)与有一个以上基线突变的患者相比,差异无统计学意义。放疗后初始ctDNA阳性的患者与ctDNA阴性的患者相比,PFS(P=0.047)和OS(P=0.005)显著降低。放疗后血浆ctDNA状态是单因素和多因素分析的独立预后因素。对随访期间ctDNA的动态监测进行了检查。结果表明,ctDNA是接受根治性放疗的ESCC患者的预测和预后标志物,可指导后续治疗。